Procedures
Participants who fulfilled the study criteria were randomly assigned in a 1:1 ratio to receive liraglutide 3.0 mg or a placebo, which was administered subcutaneously using pen injectors. After a dose escalation period starting at 0.6 mg q.d., there were weekly increments of 0.6 mg (see Fig. 